These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 2733792)

  • 1. Vesicular removal by oligodendrocytes of membrane attack complexes formed by activated complement.
    Scolding NJ; Morgan BP; Houston WA; Linington C; Campbell AK; Compston DA
    Nature; 1989 Jun; 339(6226):620-2. PubMed ID: 2733792
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complement activation in autoimmune demyelination: dual role in neuroinflammation and neuroprotection.
    Rus H; Cudrici C; Niculescu F; Shin ML
    J Neuroimmunol; 2006 Nov; 180(1-2):9-16. PubMed ID: 16905199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-heat shock protein 90beta antibodies decrease pre-oligodendrocyte population in perinatal and adult cell cultures. Implications for remyelination in multiple sclerosis.
    Cid C; Alvarez-Cermeño JC; Salinas M; Alcázar A
    J Neurochem; 2005 Oct; 95(2):349-60. PubMed ID: 16135098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human oligodendrocytes are not sensitive to complement. A study of CD59 expression in the human central nervous system.
    Zajicek J; Wing M; Skepper J; Compston A
    Lab Invest; 1995 Jul; 73(1):128-38. PubMed ID: 7541492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The oligodendroglial cell: biology and immunology and relationship to multiple sclerosis.
    Bartlett PF; Mackay IR
    J Clin Lab Immunol; 1983 May; 11(1):1-7. PubMed ID: 6348293
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reversible injury of cultured rat oligodendrocytes by complement.
    Scolding NJ; Houston WA; Morgan BP; Campbell AK; Compston DA
    Immunology; 1989 Aug; 67(4):441-6. PubMed ID: 2767708
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The complement system in central nervous system diseases.
    Rus H; Cudrici C; David S; Niculescu F
    Autoimmunity; 2006 Aug; 39(5):395-402. PubMed ID: 16923539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Homogeneity of active demyelinating lesions in established multiple sclerosis.
    Breij EC; Brink BP; Veerhuis R; van den Berg C; Vloet R; Yan R; Dijkstra CD; van der Valk P; Bö L
    Ann Neurol; 2008 Jan; 63(1):16-25. PubMed ID: 18232012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Normal rat serum cytotoxicity against syngeneic oligodendrocytes. Complement activation and attack in the absence of anti-myelin antibodies.
    Scolding NJ; Morgan BP; Houston A; Campbell AK; Linington C; Compston DA
    J Neurol Sci; 1989 Feb; 89(2-3):289-300. PubMed ID: 2926453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Antibodies to myelin cerebrosides and their role in the pathogenesis of autoimmune demyelinating diseases (review)].
    Taranova NP; Kirchik OS
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1985; 85(12):1863-72. PubMed ID: 3911691
    [No Abstract]   [Full Text] [Related]  

  • 11. Characterization of antioligodendrocyte serum.
    Traugott U; Snyder S; Norton WT; Raine CS
    Ann Neurol; 1978 Nov; 4(5):431-9. PubMed ID: 367262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-disialoside antibodies kill perisynaptic Schwann cells and damage motor nerve terminals via membrane attack complex in a murine model of neuropathy.
    Halstead SK; O'Hanlon GM; Humphreys PD; Morrison DB; Morgan BP; Todd AJ; Plomp JJ; Willison HJ
    Brain; 2004 Sep; 127(Pt 9):2109-23. PubMed ID: 15289269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interactions between oligodendrocytes and microglia. A major role for complement and tumour necrosis factor in oligodendrocyte adherence and killing.
    Zajicek JP; Wing M; Scolding NJ; Compston DA
    Brain; 1992 Dec; 115 ( Pt 6)():1611-31. PubMed ID: 1486453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oligodendrocyte-macrophage interactions in vitro triggered by specific antibodies.
    Scolding NJ; Compston DA
    Immunology; 1991 Jan; 72(1):127-32. PubMed ID: 1997396
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple sclerosis: in situ evidence for antibody- and complement-mediated demyelination.
    Storch MK; Piddlesden S; Haltia M; Iivanainen M; Morgan P; Lassmann H
    Ann Neurol; 1998 Apr; 43(4):465-71. PubMed ID: 9546327
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oligodendrocytes and oligodendrocyte/type-2 astrocyte progenitor cells of adult rats are specifically susceptible to the lytic effects of complement in absence of antibody.
    Wren DR; Noble M
    Proc Natl Acad Sci U S A; 1989 Nov; 86(22):9025-9. PubMed ID: 2813437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activated terminal complement in cerebrospinal fluid in Guillain-Barré syndrome and multiple sclerosis.
    Sanders ME; Koski CL; Robbins D; Shin ML; Frank MM; Joiner KA
    J Immunol; 1986 Jun; 136(12):4456-9. PubMed ID: 3711661
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oligodendrocyte susceptibility to injury by T-cell perforin.
    Scolding NJ; Jones J; Compston DA; Morgan BP
    Immunology; 1990 May; 70(1):6-10. PubMed ID: 2354862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NMDA receptors mediate calcium accumulation in myelin during chemical ischaemia.
    Micu I; Jiang Q; Coderre E; Ridsdale A; Zhang L; Woulfe J; Yin X; Trapp BD; McRory JE; Rehak R; Zamponi GW; Wang W; Stys PK
    Nature; 2006 Feb; 439(7079):988-92. PubMed ID: 16372019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of kainate receptors sensitizes oligodendrocytes to complement attack.
    Alberdi E; Sánchez-Gómez MV; Torre I; Domercq M; Pérez-Samartín A; Pérez-Cerdá F; Matute C
    J Neurosci; 2006 Mar; 26(12):3220-8. PubMed ID: 16554473
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.